Abstract
γ-Secretase inhibitors are new anti-cancer agents targeting Notch signaling. Their specificity for Notch is as yet unclear. Han and colleagues investigated the effects of Z-LeuLeuNleu-CHO on growth of breast cancer cells. The results demonstrated a reduction in cell viability primarily via proteasome inhibition independent of Notch activity. Currently, γ-secretase inhibitors in clinical trials are structurally distinct from Z-LeuLeuNleu-CHO. Their effects on the proteasome are yet to be determined. However, findings from Han and colleagues pose two critical questions: Is the level of proteasomal activity in breast tumors the driving force for growth? What does the Notch pathway contribute to this growth?© 2009 BioMed Central Ltd.
Cite
CITATION STYLE
Clementz, A. G., & Osipo, C. (2009, October 15). Notch versus the proteasome: What is the target of γ-secretase inhibitor-I? Breast Cancer Research. https://doi.org/10.1186/bcr2407
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.